1 citations
,
April 2024 in “Journal of Pharmaceutical and Pharmacological Sciences” The mouse models are effective for testing new hair loss treatments.
1 citations
,
July 2022 in “JEADV Clinical Practice” New and existing treatments for hair loss show promise, with some being more effective for men and others for women.
December 2025 in “International Journal of Innovative Technologies in Social Science” New treatments for androgenetic alopecia show promise but need more research for validation.
Recent research on androgenetic alopecia focuses on optimizing treatments, with promising new therapies emerging.
July 2024 in “Forum Dermatologicum” Topical treatments for hair loss can be effective but need careful safety evaluation.
There are many treatments for common hair loss, but more trials are needed to decide which are best.
August 2025 in “Journal of Cosmetic Dermatology” Interest in new and personalized treatments for hair loss is growing.
March 2026 in “Frontiers in Pharmacology” New treatments for hair loss show promise but need more testing for effectiveness and safety.
December 2025 in “IP Indian Journal of Clinical and Experimental Dermatology” Androgenetic alopecia treatments are becoming more personalized and include new therapies like topical antiandrogens and regenerative strategies.
3 citations
,
November 1998 in “PubMed”
March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)” De nouvelles thérapies promettent de mieux traiter la perte de cheveux due à l'alopécie androgénétique.
January 2025 in “Annals of Dermatology” New treatments for hair loss include low-dose oral minoxidil, light therapy, and innovative therapies targeting hair growth mechanisms.
17 citations
,
October 2006 in “Molecular and Cellular Endocrinology” The L457(3.43)R mutation in the human lutropin receptor causes increased activity and hormone insensitivity, leading to precocious puberty.
16 citations
,
April 2014 in “Expert Opinion on Pharmacotherapy” Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
36 citations
,
June 2014 in “Experimental Neurology” Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.
39 citations
,
September 2015 in “Clinical Therapeutics” Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
March 2023 in “Scientific Reports” Using focused ultrasound on the brain can help epilepsy medicine work better in rats.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
3 citations
,
October 2024 in “Advances in Therapy” Triptorelin effectively treats central precocious puberty in Chinese children with minimal side effects.
4 citations
,
December 2024 in “European Journal of Medicinal Chemistry” New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.
2 citations
,
November 2022 in “Biosensors” A new, efficient method has been developed to detect darolutamide and thalidomide, drugs used for certain hair loss and prostate cancer treatments, in pharmaceuticals and body fluids.
84 citations
,
August 2023 in “Drugs” Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
September 2013 in “Neurodegenerative disease management” Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.
November 2012 in “Journal of Clinical Pathology” December 2013 in “Urology reports (St - Petersburg)” Sonirid Duo effectively treats benign prostatic hyperplasia.
137 citations
,
December 2006 in “Arthritis Research & Therapy” Mycophenolate mofetil is safer and more effective than cyclophosphamide for treating lupus nephritis.
16 citations
,
April 2006 in “Pediatrics International” High-dose mizoribine effectively controls symptoms in adolescents with lupus while reducing steroid use, with manageable side effects.
253 citations
,
April 2014 in “Drugs” Teriflunomide helps reduce multiple sclerosis symptoms and is safe for most patients.
22 citations
,
May 2003 in “Planta Medica” Torilin from Torilis japonica can inhibit testosterone 5α-reductase but is less effective than finasteride.